Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer.
about
Network Biomarkers of Bladder Cancer Based on a Genome-Wide Genetic and Epigenetic Network Derived from Next-Generation Sequencing Data.Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targetsA High Affinity hRpn2-Derived Peptide That Displaces Human Rpn13 from Proteasome in 293T Cells.The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle ProgressionCharacterization of Dynamic UbR-Proteasome Subcomplexes by In vivo Cross-linking (X) Assisted Bimolecular Tandem Affinity Purification (XBAP) and Label-free Quantitation.A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cellsProteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi.ADRM1-amplified metastasis gene in gastric cancer.Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.Structures of Rpn1 T1:Rad23 and hRpn13:hPLIC2 Reveal Distinct Binding Mechanisms between Substrate Receptors and Shuttle Factors of the Proteasome.Proteasome dysregulation in human cancer: implications for clinical therapies.Structure and energetics of pairwise interactions between proteasome subunits RPN2, RPN13, and ubiquitin clarify a substrate recruitment mechanism.Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer
P2860
Q31066313-861BD60A-8A0E-4BE0-B265-A1594A911005Q33862782-876B3A89-4A04-43F0-AD74-064CDDB857F6Q35806570-12FC5EE0-344E-4F8C-B207-FC0BAC7FA03AQ36884720-480696CA-C7AA-4214-8A77-B62545CCB63DQ37076872-05571A3A-4859-4EA8-A972-FC00E7686211Q37435436-09E14BB5-AF39-47E6-A966-9282028AA021Q37684367-71276730-7BE1-43D0-A46E-28906C8EFC0CQ38711624-A64F7064-7A02-4B27-9910-F0C92C03ECAEQ38866440-D4DC64DC-76E0-4571-BD5A-479260D431DFQ41291592-B2794629-AD64-41F1-A1C1-1D5EE7B52687Q42382149-7E6E2D53-144F-4A10-B623-0F71EA00463BQ50077966-A02AAE07-06AD-4B62-A387-CFD864E1A600Q51035419-6B646CD8-4248-427F-9633-9F64E7816BE3Q57063488-29A154F2-C0E8-4DD1-993F-D054DE64B5CF
P2860
Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Amplification Target ADRM1: Ro ...... tic Target for Ovarian Cancer.
@ast
Amplification Target ADRM1: Ro ...... tic Target for Ovarian Cancer.
@en
type
label
Amplification Target ADRM1: Ro ...... tic Target for Ovarian Cancer.
@ast
Amplification Target ADRM1: Ro ...... tic Target for Ovarian Cancer.
@en
prefLabel
Amplification Target ADRM1: Ro ...... tic Target for Ovarian Cancer.
@ast
Amplification Target ADRM1: Ro ...... tic Target for Ovarian Cancer.
@en
P2093
P2860
P356
P1476
Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer
@en
P2093
Dennis J Slamon
Erika M von Euw
Gottfried E Konecny
Lee Anderson
Marlena S Fejzo
Michael J Haykinson
Nuraly K Avliyakulov
Richard S Finn
P2860
P304
P356
10.3390/IJMS14023094
P407
P577
2013-02-01T00:00:00Z